NT-proBNP

NT-proBNP immunoassay soon on clinical chemistry platforms

The Gentian NT-proBNP Immunoassay is positioned as an aid in the diagnosis and assessment of severity in individuals suspected of having heart failure (HF). Measurement of NT-proBNP on fast, cost-effective and high-volume clinical analysers will fulfil the need for accurate and faster diagnosis of cardiac diseases. 

Gentian’s proprietary antibody and nanoparticle-based technology will allow for comparable, consistent, biotin interference-free measurement of clinically relevant concentrations of NT-proBNP. Moving NT-proBNP to high volume and easily accessible clinical chemistry analysers can generate laboratory productivity gain.

• Open channel - the assay can run on open clinical chemistry analysers independent of the platform provider
• Measure concentrations in clinical relevant ranges, even at low levels 
• No biotin interference

Heart Failure and NT-proBNP

Heart failure is a global health issue affecting more than 26 million people worldwide. The prevalence of heart failure is increasing rapidly due to the ageing population and  increased risk factors, like diabetes and hypertension.

NT-proBNP is a standard blood test for individuals suspected of having heart failure (HF) where measurements of NT-proBNP are used as an aid in the diagnosis and assessment of severity. 

Brain natriuretic peptide (BNP)

Brain natriuretic peptide (BNP) is a hormone that is secreted by cardiomyocytes (cardiac muscle cells) in the heart ventricles in response to stretching caused by cardiac wall stress. BNP forms part of the natriuretic peptide family, along with the two other natriuretic peptides, ANP and CNP. Together, the natriuretic peptides promote urine secretion, relax the blood vessels, lower the blood pressure, and reduces the heart’s workload.

ANP and BNP secretion from the myocardium is stimulated by mechanical stress and/or neurohormonal stimulation. This illustration is adapted from Semenov AG, Feygina EE. Standardization of BNP and NT-proBNP Immunoassays in Light of the Diverse and Complex Nature of Circulating BNP-Related Peptides. Adv Clin Chem. 2018

BNP and the N-terminal part of the BNP precursor molecule, NT-proBNP, are established, benchmark diagnostic and prognostic markers for myocardial function. BNP and NT-proBNP have high negative predictive values, and clinical guidelines recommend measuring either BNP or NT-proBNP to rule out heart failure¹. The clinical cut-off levels are low, however, the reference range for NT-proBNP vary with age and gender. Women have higher NT-proBNP levels than men, and the concentration of NT-proBNP also increases with age. The expected NT-proBNP can also be used to monitor treatment for patients with chronic heart failure², and for prognosis of heart failure.

Contact us for early adoption program

Would you like to know more about our NT-proBNP immunoassay? 

Let us know if you are interested in OEM or distribution opportunities, or to validate the assay in your lab at the time of launch. Please send us an email to marketing@gentian.com or fill out the form below and our Product Manager for NT-proBNP will get in touch.

References:

1. Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016.
2. National Guideline Centre (UK). Chronic Heart Failure in Adults: Diagnosis and Management. London: National Institute for Health and Care Excellence (UK); 2018
3. Srisawasdi P et al. The effect of renal dysfunction on BNP, NT-proBNP, and their ratio. Am J Clin Pathol. 2010